Tag: Cancer: Prostate

Talazoparib + enzalutamide linked to improved survival for patients with mCRPC unselected for HRR gene alterations

127 patients underwent prostate biopsy, with 94 prostate cancers diagnosed; 86.2 percent had clinically significant disease

Risk for death significantly lower for patients with return of serum testosterone to normal range value

Clinically significant improvement seen in fatigue, and improvement seen in relative peak aerobic capacity with 12-week exercise regimen

Acute genitourinary, GI toxicity linked to late genitourinary or GI toxicity and decrement in urinary or bowel quality of life

MPS2 provides meaningful improvement in detection of grade group ≥2 cancer relative to PSA-based testing approaches

At the same time, incidence of distant-stage prostate cancer increased

No significant associations seen for SLE or AS with prostate cancer or in reverse MR analyses

Tests do not consistently influence risk classification or treatment decisions; authors call for well-designed trials on role of GC tests in newly diagnosed PCa

M1 disease detected with PSMA-PET in 46 percent of patients with high-risk, nonmetastatic hormone-sensitive prostate cancer